WiCON | Pharma China (Web Edition)

Editorials

WiCON International Group
21 Bridge Street
Metuchen, NJ 08840,
USA
Tel/Fax: +1 801-751-5728
Email: info@pharmachinaonline.com

China Head Office
c/o Beijing Jicai PharmTech
Oriental Kenzo Plaza
Beijing, China
Tel: +86 10 84476010
Email:
info@pharmachinaonline.com

As MNCs Refocus on Innovative Drugs, Feel the Pulse of China's IP Landscape Chief Editor James Shen offers his monthly review of the Chinese healthcare sector with this issue's emphasis on latest market data, national VBP tender outcomes and mixe...
(9/2/2020)

NMPA and CNIPA issue Draft Patent Linkage Measures in China (9/18/2020)

China's Draft Patent Linkage Implementation Measures for Public Comment (9/17/2020)

Chinese Consumers Increasingly Prioritize Immune Health (9/16/2020)

Anheart Builds Its Oncology Pipeline Following Five Rs (9/15/2020)

With U.S.-China Relations Tremulous, Is China Still a Good Place to Do Business? (9/15/2020)

China Debates Cutting US Access to Drugs as Hostilities Spike (9/9/2020)

China Tightens Technology Export Control Rules (9/3/2020)

As MNCs Refocus on Innovative Drugs, Feel the Pulse of China's IP Landscape (9/2/2020)

China's Pre-Revenue Biopharma Players Continue To Be Embraced By Markets, Investors (9/1/2020)

McKinsey Report: Managing China's Growing Oncology Burden (8/30/2020)

Data-Driven Perspectives on US-China Business (8/28/2020)

Chinabio Partnering Panel Says Outlook Is Positive for Investments (8/28/2020)

China Could Weaponize Drug Exports to Retaliate Against US Chip Restrictions (8/26/2020)

Foreign Drug Giants Undercut by Up to 95% in China Bidding (8/21/2020)

First Ever Preliminary Injunction Issued By Chinese Court In Pharmaceutical Patent Case (8/13/2020)

Recent Executive Moves (9/18/2020) REMD In-licenses Bispecific Antibody from GenS... (9/18/2020) Raziel Announces China License Deal with Fosun... (9/18/2020) MorphoSys and I-Mab Cleared by FDA for IND o... (9/18/2020) WiCON Publishes the China Pharmaceutical Guide... (9/18/2020) (free) Dyadic Announces Collaboration with Jiangsu He... (9/17/2020) Supreme Court and NHSA Enter MOU for Establish... (9/17/2020) Snapshot of Chinese Internet Healthcare Market (9/17/2020) Genetron Health and dMed Announce Partnership ... (9/16/2020) NHSA Issues the Guidance Opinions for Establis... (9/16/2020) NMPA Suspends Import, Sales and Use of Poliche... (9/16/2020) J&J Granted Clinical Trial Approvals for Amiva... (9/16/2020) Croma and CNBG Form New Aesthetic Medicine JV ... (9/16/2020) China's First COVID-19 Virus Vaccine Patent Gr... (9/16/2020) (free) AnHeart Licenses Two Clinical Stage Oncology C... (9/15/2020)

Pfizer to Absorb Mylan, Creating Global Generic Powerho... PhRMA Calls for Trade Deals That Force Countries to Pay... IQVIA: Global Pharma to Grow Slower in the Next Five Ye... Pfizer and GSK Announce JV to Create a Global Consumer ... Top 25 Global Pharmaceutical Companies by Market Cap 20...

WiCON Publishes the China Pharmaceutical Guide 2020 (15... Snapshot of Chinese Internet Healthcare Market SMEI: Urban Hospital Chemical Drug Market Down Sharply ... IQVIA: Chinese Retail Pharmacy Sales Up Only 1.2% in Q1... Sinohealth CMH: Chinese Drug Market Rose 8.9% in 2019 B...

Raziel Announces China License Deal with Fosun Pharma f... REMD In-licenses Bispecific Antibody from GenScript Pro... Dyadic Announces Collaboration with Jiangsu Hengrui Med... Croma and CNBG Form New Aesthetic Medicine JV in China Genetron Health and dMed Announce Partnership for New D...

NMPA Suspends Import, Sales and Use of Polichem's Nifur... CDE Issues Document on Re-registration of Foreign-made ... CDE Solicits Comments on the Essential Technical Requir... NMPA and CNIPA Solicit Comments on the Draft Implementa... CDE Solicits Comments on the Draft Technical Guidelines...

Supreme Court and NHSA Enter MOU for Establishing Pharm... CNIPA Invalidates BMS‘s Chinese Patent for Low Dose En... Illumina Sues BGI Over Coronavirus Patent Infringement Chinese Biotech Researcher Pleads Guilty to Stealing Tr... NPC Solicits Comments on 2nd Draft of the Chinese Paten...

U.S. Introduces A 'Buy American First' Pharma Executive... Fitch: No Near-Term Impact on Chinese API Makers as Pha... Indian Firms Challenged by API Price Hikes by Chinese S... Snapshot of the Chinese API Sector India to Boost API Output as Alternative Source to Chin...

MorphoSys and I-Mab Cleared by FDA for IND of Antican... China's First COVID-19 Virus Vaccine Patent Granted to ... J&J Granted Clinical Trial Approvals for Amivantamab an... China Grants Priority Review Status to Roche's NDAs for... Everest Reports on P1 Trial of Taniborbactam in Combo w...

NHSA Issues the Guidance Opinions for Establishing Drug... China Issues the Guidance Policy for Strengthening and ... Vice Premier Calls for Deepened Reform of Centralized D... New NHSA Guidance Document Calls for Drug Price Surveil... China Considers to Regulate Online Healthcare Mutual Ai...

Recent Executive Moves Recent Executive Moves Recent Executive Moves Recent Official and Executive Moves Recent Executive Moves

USTR Satisfied with China's Implementatin of Phase 1 US... U.S.-China ESRC Hearing: China's Evolving Healthcare Sy... AmCham Survey: Supply Chain Challenges for US Companies... Upcoming Event: 2nd World Congress on Dermatology and A... Upcoming Event: XI International Exhibition of Equipmen...

Pharma China is the most influential English media and source of business intelligence covering the Chinese pharmaceutical and biopharmaceutical sector...

WiCON has been helping international healthcare companies succeed in China and other Asian markets since 1991. We advise our clients on every stage of their China and Asian business. We worked with clients in many regions of the world...

WiCON Publishes the China Pharmaceu... WiCON Publishes the China Pharmaceu... WiCON to Hold Pharma China Annual F... WiCON Publishes the China Pharmaceu... WiCON Officially Publishes China Ph...